blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3292140

EP3292140 - CANCER IMMUNOTHERAPEUTIC [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  24.02.2023
Database last updated on 03.10.2024
FormerThe patent has been granted
Status updated on  18.03.2022
FormerGrant of patent is intended
Status updated on  02.11.2021
FormerExamination is in progress
Status updated on  25.03.2020
FormerRequest for examination was made
Status updated on  09.02.2018
FormerThe international publication has been made
Status updated on  11.11.2016
Most recent event   Tooltip13.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 16.10.2024 [2024/42]
Applicant(s)For all designated states
Rubicon Biotechnology LLC
26212 Dimension Drive
Suite 260
Lake Forest, CA 92630 / US
[2018/11]
Inventor(s)01 / PARSEGHIAN, Missag
c/o Rubicon Biotechnology LLC
26212 Dimension Drive
Suite 260
Lake Forest, CA 92630 / US
02 / RICHIERI, Richard
c/o Rubicon Biotechnology LLC
26212 Dimension Drive
Suite 260
Lake Forest, CA 92630 / US
03 / REYNOLDS, Glenn
c/o Rubicon Biotechnology LLC
26212 Dimension Drive
Suite 260
Lake Forest, CA 92630 / US
 [2018/11]
Representative(s)HGF
HGF Limited
1 City Walk
Leeds LS11 9DX / GB
[2022/16]
Former [2018/11]HGF Limited
Saviour House
9 St. Saviourgate
York YO1 8NQ / GB
Application number, filing date16790111.505.05.2016
[2018/11]
WO2016US31049
Priority number, dateUS201562157395P05.05.2015         Original published format: US 201562157395 P
[2018/11]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016179430
Date:10.11.2016
Language:EN
[2016/45]
Type: A1 Application with search report 
No.:EP3292140
Date:14.03.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 10.11.2016 takes the place of the publication of the European patent application.
[2018/11]
Type: B1 Patent specification 
No.:EP3292140
Date:20.04.2022
Language:EN
[2022/16]
Search report(s)International search report - published on:US10.11.2016
(Supplementary) European search report - dispatched on:EP29.11.2018
ClassificationIPC:A61K47/68, C07K14/47, A61K8/14, C07K14/54, C07K16/18, A61K47/42, A61K39/395, A61P35/00, C07K14/525
[2019/01]
CPC:
A61K47/6811 (EP,US); A61K47/68 (EP,US); A61P35/00 (EP,US);
C07K14/4721 (EP,US); C07K14/525 (EP,US); C07K2319/00 (EP,US);
C07K2319/30 (EP,US); G01N33/68 (US) (-)
Former IPC [2018/11]C07K14/47, C07K14/54, C07K16/18, A61K47/42, A61K39/395, A61K8/14, G01N33/68
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/11]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:IMMUNOTHERAPEUTIKUM GEGEN KREBS[2018/11]
English:CANCER IMMUNOTHERAPEUTIC[2018/11]
French:IMMUNOTHÉRAPIE DU CANCER[2018/11]
Entry into regional phase04.12.2017National basic fee paid 
04.12.2017Search fee paid 
04.12.2017Designation fee(s) paid 
04.12.2017Examination fee paid 
Examination procedure04.12.2017Examination requested  [2018/11]
04.12.2017Date on which the examining division has become responsible
26.06.2019Amendment by applicant (claims and/or description)
30.03.2020Despatch of a communication from the examining division (Time limit: M06)
09.10.2020Reply to a communication from the examining division
16.02.2021Despatch of a communication from the examining division (Time limit: M04)
28.06.2021Reply to a communication from the examining division
03.11.2021Communication of intention to grant the patent
11.03.2022Fee for grant paid
11.03.2022Fee for publishing/printing paid
11.03.2022Receipt of the translation of the claim(s)
Divisional application(s)EP22163069.2  / EP4079328
Opposition(s)23.01.2023No opposition filed within time limit [2023/13]
Fees paidRenewal fee
11.05.2018Renewal fee patent year 03
15.05.2019Renewal fee patent year 04
14.05.2020Renewal fee patent year 05
15.07.2021Renewal fee patent year 06
Penalty fee
Additional fee for renewal fee
31.05.202106   M06   Fee paid on   15.07.2021
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU05.05.2016
AL20.04.2022
AT20.04.2022
CY20.04.2022
CZ20.04.2022
EE20.04.2022
FI20.04.2022
HR20.04.2022
LT20.04.2022
LV20.04.2022
MC20.04.2022
MK20.04.2022
MT20.04.2022
NL20.04.2022
PL20.04.2022
RO20.04.2022
RS20.04.2022
SE20.04.2022
SI20.04.2022
SK20.04.2022
SM20.04.2022
TR20.04.2022
IE05.05.2022
LU05.05.2022
BE31.05.2022
BG20.07.2022
NO20.07.2022
GR21.07.2022
IS20.08.2022
PT22.08.2022
[2024/42]
Former [2024/29]HU05.05.2016
AL20.04.2022
AT20.04.2022
CY20.04.2022
CZ20.04.2022
EE20.04.2022
FI20.04.2022
HR20.04.2022
LT20.04.2022
LV20.04.2022
MC20.04.2022
MK20.04.2022
NL20.04.2022
PL20.04.2022
RO20.04.2022
RS20.04.2022
SE20.04.2022
SI20.04.2022
SK20.04.2022
SM20.04.2022
TR20.04.2022
IE05.05.2022
LU05.05.2022
BE31.05.2022
BG20.07.2022
NO20.07.2022
GR21.07.2022
IS20.08.2022
PT22.08.2022
Former [2024/22]HU05.05.2016
AL20.04.2022
AT20.04.2022
CY20.04.2022
CZ20.04.2022
EE20.04.2022
FI20.04.2022
HR20.04.2022
LT20.04.2022
LV20.04.2022
MC20.04.2022
MK20.04.2022
NL20.04.2022
PL20.04.2022
RO20.04.2022
RS20.04.2022
SE20.04.2022
SI20.04.2022
SK20.04.2022
SM20.04.2022
IE05.05.2022
LU05.05.2022
BE31.05.2022
BG20.07.2022
NO20.07.2022
GR21.07.2022
IS20.08.2022
PT22.08.2022
Former [2024/20]HU05.05.2016
AL20.04.2022
AT20.04.2022
CY20.04.2022
CZ20.04.2022
EE20.04.2022
FI20.04.2022
HR20.04.2022
LT20.04.2022
LV20.04.2022
MC20.04.2022
NL20.04.2022
PL20.04.2022
RO20.04.2022
RS20.04.2022
SE20.04.2022
SI20.04.2022
SK20.04.2022
SM20.04.2022
IE05.05.2022
LU05.05.2022
BE31.05.2022
BG20.07.2022
NO20.07.2022
GR21.07.2022
IS20.08.2022
PT22.08.2022
Former [2024/18]HU05.05.2016
AL20.04.2022
AT20.04.2022
CZ20.04.2022
EE20.04.2022
FI20.04.2022
HR20.04.2022
LT20.04.2022
LV20.04.2022
MC20.04.2022
NL20.04.2022
PL20.04.2022
RO20.04.2022
RS20.04.2022
SE20.04.2022
SI20.04.2022
SK20.04.2022
SM20.04.2022
IE05.05.2022
LU05.05.2022
BE31.05.2022
BG20.07.2022
NO20.07.2022
GR21.07.2022
IS20.08.2022
PT22.08.2022
Former [2023/25]AL20.04.2022
AT20.04.2022
CZ20.04.2022
EE20.04.2022
FI20.04.2022
HR20.04.2022
LT20.04.2022
LV20.04.2022
MC20.04.2022
NL20.04.2022
PL20.04.2022
RO20.04.2022
RS20.04.2022
SE20.04.2022
SI20.04.2022
SK20.04.2022
SM20.04.2022
IE05.05.2022
LU05.05.2022
BE31.05.2022
BG20.07.2022
NO20.07.2022
GR21.07.2022
IS20.08.2022
PT22.08.2022
Former [2023/20]AL20.04.2022
AT20.04.2022
CZ20.04.2022
EE20.04.2022
FI20.04.2022
HR20.04.2022
LT20.04.2022
LV20.04.2022
MC20.04.2022
NL20.04.2022
PL20.04.2022
RO20.04.2022
RS20.04.2022
SE20.04.2022
SK20.04.2022
SM20.04.2022
IE05.05.2022
LU05.05.2022
BG20.07.2022
NO20.07.2022
GR21.07.2022
IS20.08.2022
PT22.08.2022
Former [2023/17]AL20.04.2022
AT20.04.2022
CZ20.04.2022
EE20.04.2022
FI20.04.2022
HR20.04.2022
LT20.04.2022
LV20.04.2022
MC20.04.2022
NL20.04.2022
PL20.04.2022
RO20.04.2022
RS20.04.2022
SE20.04.2022
SK20.04.2022
SM20.04.2022
LU05.05.2022
BG20.07.2022
NO20.07.2022
GR21.07.2022
IS20.08.2022
PT22.08.2022
Former [2023/09]AT20.04.2022
CZ20.04.2022
EE20.04.2022
FI20.04.2022
HR20.04.2022
LT20.04.2022
LV20.04.2022
MC20.04.2022
NL20.04.2022
PL20.04.2022
RO20.04.2022
RS20.04.2022
SE20.04.2022
SK20.04.2022
SM20.04.2022
LU05.05.2022
BG20.07.2022
NO20.07.2022
GR21.07.2022
IS20.08.2022
PT22.08.2022
Former [2023/08]AT20.04.2022
FI20.04.2022
HR20.04.2022
LT20.04.2022
LV20.04.2022
MC20.04.2022
NL20.04.2022
PL20.04.2022
RS20.04.2022
SE20.04.2022
LU05.05.2022
BG20.07.2022
NO20.07.2022
GR21.07.2022
IS20.08.2022
PT22.08.2022
Former [2022/51]AT20.04.2022
FI20.04.2022
HR20.04.2022
LT20.04.2022
LV20.04.2022
NL20.04.2022
PL20.04.2022
RS20.04.2022
SE20.04.2022
BG20.07.2022
NO20.07.2022
GR21.07.2022
IS20.08.2022
PT22.08.2022
Former [2022/50]AT20.04.2022
FI20.04.2022
HR20.04.2022
LT20.04.2022
LV20.04.2022
NL20.04.2022
PL20.04.2022
RS20.04.2022
SE20.04.2022
BG20.07.2022
NO20.07.2022
GR21.07.2022
PT22.08.2022
Former [2022/49]AT20.04.2022
FI20.04.2022
HR20.04.2022
LT20.04.2022
LV20.04.2022
NL20.04.2022
SE20.04.2022
BG20.07.2022
NO20.07.2022
GR21.07.2022
PT22.08.2022
Former [2022/47]AT20.04.2022
FI20.04.2022
LT20.04.2022
NL20.04.2022
SE20.04.2022
NO20.07.2022
PT22.08.2022
Former [2022/44]NL20.04.2022
Documents cited:Search[X]WO2007100904  (REGENT OF THE UNIVERSITY OF OK [US], et al) [X] 1-6,12-15* paragraphs [0040] , [0093]; example 3 *;
 [XI]WO2010140886  (MOSAMEDIX BV [NL], et al) [X] 1-6,8,10,12-14 * whole document, in particular page 2, lines 12-17; page 3, lines 25-36; page 5, lines 4-15 * [I] 7,9,11,15
International search[Y]WO2006079120  (UNIV TEXAS [US], et al) [Y] 1-3, 4/1-3, 17, 28-34, 35/32-34, 36-49 * ; abstract; page 5, paragraph 7; page 11, paragraphs 3-4; page 22, paragraph 2; page 36, paragraph 3; page 49, paragraph 3; page 50, paragraph 3; page 53, paragraph 4; page 67, paragraph 2; page 79, paragraphs 2-3; page 95, paragraph 1; page 97, paragraph 2; page 110, paragraph 1; page 127, paragrap *;
 [Y]US2009155170  (REUTELINGSPERGER CHRISTIAAN PE [NL], et al) [Y] 1-3, 4/1-3, 17, 28-34, 35/32-34, 36-49 * ; abstract; paragraphs [0020], [0023]; SEQ ID NO. 1; figure 1 *;
 [Y]  - TAIT, JF et al., "Phospholipid Binding of Annexin V: Effects of Calcium and Membrane Phosphatidylserine Content.", Archives of Biochemistry and Biophysics., (19921000), vol. 298, no. 1, pages 187 - 191, XP024760656 [Y] 36 * ; page 189, column 2, paragraph 1; DOI:10.1016/0003-9861(92)90111-9 *

DOI:   http://dx.doi.org/10.1016/0003-9861(92)90111-9
Examination   - ALLAVENA ET AL, "The inflammatory micro-environment in tumor progression: The role of tumor-associated macrophages", CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY, ELSEVIER, AMSTERDAM, NL, (20071029), vol. 66, no. 1, doi:10.1016/J.CRITREVONC.2007.07.004, ISSN 1040-8428, pages 1 - 9, XP022512187

DOI:   http://dx.doi.org/10.1016/j.critrevonc.2007.07.004
    - Sandeep Rajput ET AL, "Roles of inflammation in cancer initiation progression and metastasis", Frontiers in Bioscience (Scholar Edition), Searington, US, (20100101), vol. S2, no. 1, doi:10.2741/s55, ISSN 1945-0516, pages 176 - 183, XP055679720

DOI:   http://dx.doi.org/10.2741/s55
by applicantUS2002110868
 US6878370
 US7056695
 US7118750
 US2007172449
 US2007207961
 US7446174
 US2009155170
 US7642340
 US7892558
    - UNGETHUM, Journal of Biological Chemistry, (20110000), vol. 286, no. 3, pages 1903 - 1910
    - LIU, Immunological Reviews, (20080000), vol. 222, pages 9 - 27
    - MARTIN et al., Molecular Cell, (20010000), vol. 7, pages 867 - 877
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.